Contraline Secures $92.5 Million in Latest Series B Funding Round

Contraline secured $92.5 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Contraline Raises $92.5 million in Funding

Contraline is a Digital Health company focused on Advance NES/T Male Contraceptive into Late-Stage Development.

Investors Behind the Funding

The round was backed by the Population Council. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Contraline operates in Healthcare & Life Sciences. Contraline's Series B round shows investors are still backing digital health platforms with real scale narratives. At $93M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

Advance NES/T Male Contraceptive into Late-Stage Development

Looking Ahead

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Source reference: original announcement/article.